ArticleTherapeutic advances in drug safety2019
Precision dosing to avoid adverse drug reactions.
Article in Therapeutic advances in drug safety, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of pharmacogenomic-guided antidepressant prescribing in patients with depression: an umbrella review and updated meta-analysis.Frontiers in psychiatry · 2024Pooled it
- Mesenchymal Stem cell therapy with GHRH receptor analog resolves post-stroke vasogenic edema via modulating AQP4 and mitochondria-ER crosstalk.Journal of translational medicine · 2026Article
- Evaluating genotype-treatment interactions for high-risk medications in British general practice: a retrospective cohort study using UK Biobank.The British journal of general practice : the journal of the Royal College of General Practitioners · 2026Article
- The aspiration of precision glucocorticoid pharmacotherapy in immune-mediated diseases: where do we stand in integrating pharmacogenomics and biomarkers for individualized treatment?Frontiers in immunology · 2026Review
- Digital twins in precision pharmacotherapy: emerging applications, challenges, and future directions.Frontiers in digital health · 2026Review
- Article
- Integrating a Pharmacovigilance and Response Unit Team for a Better Adverse Drug Reaction Reporting and Management: Insights from a Prospective Cross-Sectional Study.Turkish journal of pharmaceutical sciences · 2025Article
- Barriers to and facilitators of healthcare professionals in ADR reporting in a tertiary care hospital in India.BMC health services research · 2025Article
- Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare.Pharmaceutics · 2024Review
- Artificial intelligence in pediatrics: the future is now.Pediatric research · 2023Article
- Virtual twin for healthcare management.Frontiers in digital health · 2023Article
- Validation of Pharmacogenomic Interaction Probability (PIP) Scores in Predicting Drug-Gene, Drug-Drug-Gene, and Drug-Gene-Gene Interaction Risks in a Large Patient Population.Journal of personalized medicine · 2022Article
- Semi-Automated Therapeutic Drug Monitoring as a Pillar toward Personalized Medicine for Tuberculosis Management.Pharmaceutics · 2022Review
- A 3D-Printed Polymer-Lipid-Hybrid Tablet towards the Development of Bespoke SMEDDS Formulations.Pharmaceutics · 2021Article
- Quantifying the Impact of Phenoconversion on Medications With Actionable Pharmacogenomic Guideline Recommendations in an Acute Aged Persons Mental Health Setting.Frontiers in psychiatry · 2021Article
- What Are the Current Approaches to Optimising Antimicrobial Dosing in the Intensive Care Unit?Pharmaceutics · 2020Review
- Software Tools for Model-Informed Precision Dosing: How Well Do They Satisfy the Needs?Frontiers in pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adverse drug reactions (ADRs) have traditionally been managed by trial and error, adjusting drug and dose selection reactively following patient harm. With an improved understanding of ADRs, and the patient characteristics that increase susceptibility, precision medicine technologies enable a proactive approach to ADRs and support clinicians to change prescribing accordingly. This commentary revisits the famous pharmacology-toxicology continuum first postulated by Paracelsus 500 years ago and explains why precision dosing is needed to help avoid ADRs in modern clinical practice. Strategies on how to improve precision dosing are given, including more research to establish better precision dosing targets in the cases of greatest need, easier access to dosing instructions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.